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Schizophrenia is a chronic psychiatric condition that includes 
positive (e.g., delusions), negative (e.g., lack of motivation), and 
cognitive symptoms (e.g., loss of memory). These symptoms 
can severely affect the social, educational, occupational, and 
health-related functioning of the individual.1 Antagonism at the 
dopamine D2-receptor is a common mechanism of action for cur-
rently available treatment of schizophrenia.2 However, central D2-
receptor occupancies (D2RO) >80% increase the risk of adverse 
effects (AEs) such as extrapyramidal symptoms (EPS).3
Extrapyramidal side effects of antipsychotic drugs (APs) 
include acute movement disorders, such as akathisia, and 
chronic movement disorders, such as tardive dyskinesia. In 
addition to being uncomfortable to patients, these side effects 
could behave as confounding factors and may lead to an under-
estimation of efficacy of the APs.4 In drug development, EPS 
symptoms are often assessed using rating scales, e.g., Simp-
son–Angus Scale, or by spontaneous reporting by patients, 
with severity graded by clinicians at the time of planned visits.
Atypical antipsychotics (ATAPs) were introduced to the clinic 
in an attempt to lower the EPS incidence as compared with the 
typical antipsychotics (e.g., haloperidol) and to improve the nega-
tive and cognitive symptoms of schizophrenia. One of the claims 
during marketing ATAPs is “the absence of EPS side effects”.5,6 
Recently, a meta-analysis of ATAPs vs. haloperidol using a cen-
tral tendency statistical approach to evaluate such a claim was 
performed. It demonstrated that at least some ATAPs do pro-
duce EPS and that there are differences between drugs in their 
tendency to produce EPS.6 Previously described assessments 
of EPS either looked at mean differences in Simpson–Angus 
Scale or EPS incidence on a study level7 or at indirect measure-
ments such as the prescription of anti-EPS treatment. No study 
has been published linking individual data of EPS to predictors 
such as plasma concentrations or receptor occupancy using 
pharmacokinetic–pharmacodynamic models that described the 
longitudinal aspect of EPS events following antipsychotic treat-
ment. However, de Ridder and Vermeulen8 modeled the time to 
the first treatment-emergent EPS-related event using hazard 
models, without considering the severity of the EPS events.
The discrete nature of events or discrete scales as the ones 
used for EPS assessments may call for models that are appro-
priate for the data. In the field of pharmacokinetic–pharma-
codynamic models, one usable approach is the proportional 
odds model. However, this model does not assume depen-
dency between observations and the profiles, and frequencies 
of transitions between states generated from simulations can 
be inconsistent with data. Markov elements would be needed 
to handle that property of the data. Another approach would be 
to assess the time-to-EPS of a certain severity using survival 
models, but these would not take into account serial correlation 
or that the probability of states are correlated. A “compartmen-
tal” continuous time Markov type of model is capable of estimat-
ing parameters considering time factor and hence eliminating 
the need of having frequent observations at equal spaces of 
time needed in ordinary Markov models or discrete-type mod-
els.9 A Markov-type model allows predicting the probability of 
observing a patient at any of the EPS severity grades, depend-
ing on what severity grade he or she had at the last obser-
vation and the time elapsed since the last observation. Thus, 
Markov modeling approach can help to quantify and compare 
the potency of different APs to induce EPS AEs over time.
In this analysis, the aim was to develop a continuous time, 
population-based Markov model to describe the probability 
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of EPS incidence and EPS severity as a function of dose, 
individual steady-state drug exposure (C
ss
), or predicted dop-
amine D2RO of APs. All available EPS data after the admin-
istration of placebo, four ATAPs (paliperidone-extended 
release, ziprasidone, JNJ-37822681,10 and olanzapine), and 
haloperidol from seven clinical studies were included.
reSultS
ePS data
The EPS data set consisted of 16,598 observations (rated as 
no EPS, mild, moderate, or severe) collected from 2,630 sub-
jects with acute schizophrenic condition. Of these, 594  subjects 
received placebo, 867 received paliperidone (3–15 mg/day), 437 
received olanzapine (10 or 15 mg/day), 143 received haloperidol 
(2.5–40 mg/day), 285 received ziprasidone (40–200 mg/day), 
and 301 received JNJ-37822681 treatment (10–30 mg/day). 
table 1 summarizes the trial designs and the observed EPS 
incidence rates of APs that were used in this study. Figure 1 
shows six individuals and their changes between the no–mild–
moderate/severe states. The  calculated individual-level C
ss
 and 
the predicted D2RO range (min–max) were as follows: for halo-
peridol, 1–4 ng/ml (55–98%); olanzapine, 9–76 ng/ml (44–86%); 
paliperidone, 0.5–115 ng/ml (9–95%); ziprasidone, 24–282 ng/
ml (38–89%); and JNJ-37822681, 8–178 ng/ml (35–92%).
Structural model for ePS incidence
To be able to calculate the probabilities of observing each 
EPS severity grade at any time point, the probabilities were 
determined by a Markov model with a compartmental struc-
ture using differential equations (Figure 2). The placebo model 
was first developed based on the placebo data alone. There-
after, the combined placebo and drug effects model was built 
by estimating placebo and drug effect parameters. Following 
the start of the study, the decrease of the rate constants as 
a function of time over the study period was best described 
by the exponential model (Eqs. 1 and 2). A linear model 
described the relationship between the drug exposure (Eq. 
3) and the effect of APs on the transition rate constants rea-
sonably well. Modeling the drug effect, using dose or average 
C
ss
, as proportional to the placebo effect resulted in a better 
model fit and lower relative standard errors of the parameter 
estimates, as compared with additive drug effects. E
max
 model 
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% ePS ratea 
(95% ci)c
% ePS rate, 
modelb Drug t½
SCH-303 Phase III, double-blind, 
parallel, placebo-controlled, 
randomized
6 weeks Oral/once daily Paliperidone ER 6, 9, 12 mg 335 19 (15–23) (21–30) 23 h
Olanzapine 10 mg 122 7 (2–12) — 30 h
Placebo 116 8 (3–13) (9–23) —
SCH-304 Phase III, double-blind, 
parallel, placebo-controlled, 
randomized
6 weeks Oral/once daily Paliperidone ER 6, 12 mg 199 16 (11–21) (18–30) 23 h
Olanzapine 10 mg 101 8 (3–13) — 30 h
Placebo 97 6 (1–11) (8–24) —
SCH-305 Phase III, double-blind, 
parallel, placebo-controlled, 
randomized
6 weeks Oral/once daily Paliperidone ER 3, 9, 15 mg 333 21 (17–25) (19–29) 23 h
Olanzapine 10 mg 121 7 (2–12) — 30 h
Placebo 107 7 (2–12) (9–24) —
128-114 Phase III, double-blind, 
parallel, placebo-controlled, 
randomized
6 weeks Oral/twice daily Ziprasidone 40, 80 mg 131 26 (18–34) (19–35) 7 h
Placebo 92 20 (12–28) (8–25) —
128-115 Phase III, double-blind, 
parallel, placebo-controlled, 
randomized
6 weeks Oral/twice daily Ziprasidone 20, 60, 100 mg 154 29 (22–36) (21–35) 7 h
Haloperidol 10 mg 85 59 (49–69) (63–83) 10–30 h
Placebo 82 20 (11–29) (8–24) —
SCH-2002 Phase II, double-blind, 
parallel, placebo-controlled, 
randomized
6–12 weeks Oral/twice daily JNJ-37822681 10, 20, 30 mg 301 24 (19–29) (27–36)
Olanzapine 15 mg (thrice daily) 93 15 (8–22) — 30 h
Placebo 103 6 (1–11) (8–24)
LMU Open-label study 4 weeks Oral/once daily Haloperidol 2.5–40 mg 58 95 (89–100) (72–92) 10–30 h
Demographics included in this analysis: gender: males (55%) and females (45%); race: Caucasians (67%), African-Americans (18%), Asians (7%), and others 
(6%); geographical region: United States (~41%), Eastern Europe (~35%), Asia (~10%), and other regions (~13%); and concomitant medications for treating EPS: 
anticholinergic drugs (12%), β-blockers (1.8%), and benzodiazepines (1%).
aEPS rate: (number of subjects with treatment-emergent EPS-related adverse effects (irrespective of severity)/total number of subjects randomized in a trial or 
treatment arm). b95% CI of model predictions. cAsymptotic confidence intervals.





Differential equations used to model the probability of 
observing EPS event
KF
xy and KBxy are the forward and backward transition 
probability rate constants at any given time; Base
xy , the tran-
sition probability rate constant at the start of the study; x, the 
present EPS state; y, future EPS state; t(1/2) = ln 2/kxy; t1/2, 
half-life describing the change in KF
xy or KBxy with time; drug 
effect, the effect of antipsychotic drug on KF
xy; EFF, the drug-
dependent slope parameter in relation to drug exposure; E
max
, 
the maximum drug effect on the transition rate from state x 
to state y; RO50, the model parameter that corresponds to 
compound- independent D2RO required for 50% of Emax effect 
on the  linear scale, which is then exponentiated; and A(1), 
A(2), A(3) represent the compartments for EPS probabilities.
Inclusion of interindividual variability as an exponential 
function to describe differences between patients’ sensitivity 
to treatment effects resulted in an improved model fit by objec-
tive function; however, the model was numerically unstable, 
and parameters were estimated with less precision and simu-
lation properties worsened, possibly due to non-normal dis-
tributions of empirical Bayes estimates that frequently arise 
for categorical-type models. Therefore, the model was built 
without interindividual variability in the typical parameters. 
Visit 4, scheduled to be between day 14 and day 21 (except 
LMU study), corresponds to the point in the study at which 
subjects were allowed to enter into an outpatient status. The 
improvement in the model fit and in visual predictive checks 
showed that it was important to allow some parameters to 
have different values before and after visit 4 (~day 16).
The effect of predictors was only significant to estimate for-
ward transition rate constants (i.e., KF12 and KF23). On the 
basis of NONMEM objective function value, C
ss
 was better 
than dose (decrease of ~45 objective function value units) in 
describing the drug–EPS relationships. The final EPS model 
structure (based on all drugs simultaneously) was able to 
describe the observed EPS occurrence adequately with 
acceptable low relative standard errors.
To characterize the relationship between D2RO by different 
APs and the emergence of EPS, predicted D2RO levels asso-
ciated with C
ss
 were linked to the transition rate constants by 
either using a linear function (Eq. 3) or sigmoidal function 
(Eq. 4). The advantage of this transformation is that it allows 
Q to have a value from zero to infinity for D2RO from 0 to 
100% and the drug effect to reach its maximum effect (E
max
) 
for D2RO approaching 100% (Eq. 4). This parameterization 
resulted in statistically better and numerically more stable 
estimation than using D2RO directly.
The parameter estimates of the EPS model when using 
C
ss
 and D2RO as predictors are shown in table 2. The dop-
amine D2RO needed for half of the maximum effect of APs 
on the transition rate was found to be 86.5% on the linear 
scale and 89.5 counting the exponential parameterization 
(Eq. 4). The probabilities for the different states vs. predicted 
individual D2RO (based on Css and Kd) for different APs are 
depicted in Figure 3. Probabilities of experiencing EPS 
rapidly increase at above 80% occupancy. Haloperidol and 
JNJ-37822681 exhibited higher EPS probabilities at some-
what lower D2RO levels. Although different slopes were 
found for each compound, no statistically different differ-
ences between compounds were found for the effect param-
eters of the D2RO model.
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Figure 1 Six representative individuals and their transitions between extrapyramidal symptom (EPS) states. Values on the x-axis are nominal visit 
days. The majority of the patients had no EPS, i.e., had a similar shape as patient 50,001.




For the placebo model, the maximum probability of expe-
riencing mild EPS (7%) was estimated to be around day 25, 
whereas the maximum probability of experiencing moderate/
severe EPS (1.6%) was estimated to occur at day 8. After 
these peaks, the probability slowly declines for both states.
Olanzapine was found to be less associated with EPS events 
than placebo treatment, causing difficulties in estimating the 
effect of olanzapine on EPS transitions and also causing 
model and estimation instability when analyzed simultane-
ously with the data from the other drugs. The EPS incidence 
was higher (15%) for the olanzapine arm as compared with 
the placebo treatment in one of the studies (SCH-2002), but 
individual plasma olanzapine profiles were not available from 
this study, which may have contributed to difficulties in estimat-
ing the effect of olanzapine exposure effect on the probability 
of EPS. The olanzapine data were therefore omitted from the 
analysis. Including the data and fixing the effect to zero yielded 
no significant changes to model parameters.
covariate model
Covariates were included in the model based on their statisti-
cal and clinical significance. The final EPS model included 
only one covariate in addition to in/outpatient status (regional 
difference: Eastern Europe vs. others), which was added as a 
proportional linear term to the corresponding transition prob-
ability. Residing in Eastern Europe increased the chances of 
improvement of the EPS side effects as it increased back-
ward movement probability rate constants (KB21 and KB32) by 
~100% (table 2). Not all covariate information was available 
for all trials to test the influence of covariates on the probability 
of EPS. Only paliperidone trials had co-medication and com-
plete demographic details. On the basis of paliperidone data 
only, administration of anticholinergic drug for the treatment 
of EPS was found to be an influential covariate, decreasing 
the transition probability rate constant for movement from a 
mild EPS state to moderate/severe EPS states by ~80%.
Model evaluation
The final models (table 2) were evaluated using a boot-
strap analysis with 1,000 samples. Confidence intervals of 
95% were constructed for each of the parameters and none 
of these overlapped zeros. The population estimates of the 
final model are in close agreement with the median values 
of the 952 successful bootstrap replicates. Visual predictive 
checks using 100 simulated data sets were made to evaluate 
the predictive ability of the model. The model was capable 
of satisfactorily predicting the proportions of the patients 
experiencing each of the EPS states across time (Figure 4). 
No EPS (1) Mild EPS (2) Moderate/severeEPS (3)
KF12 KF23
KB21 KB32
Figure 2 Extrapyramidal symptoms (EPS) continuous-type Markov 
model structure with compartments representing probabilities (no EPS, 
mild EPS, and pooled moderate/severe defined as compartments 1, 
2, and 3, respectively). The forward rate transitions constant KF12 and 
KF23 were allowed to be influenced by drug exposure or D2-receptor 
occupancies.
table 2 Parameter estimates (95% confidence intervals from bootstrap analysis) of the final EPS models using C
ss
 and D2-receptor occupancy as predictors of EPS
Predictor Steady-state exposure (linear model) D2-receptor occupancy (Emax model)
Parameter ≤Day 16 >Day 16 ≤Day 16 >Day 16
Base12 (day –1) 0.0178 (0.014–0.022) 0.0186 (0.015–0.022)
Base21 (day –1) 0.135 (0.104–0.17)a 0.0703 (0.051–0.096)a 0.134 (0.107–0.168)a 0.078 (0.06–0.10)a
Base23 (day –1) 0.263 (0.183–0.310) 0.0703 (0.051–0.096)a 0.369 (0.252–0.522) 0.078 (0.06–0.10)a
Base32 (day –1) 0.135 (0.104–0.17)a 0.134 (0.107–0.168)a
t½ for KF12 (days) 8.8 (7.2–10.6)a 8.9 (7.5–10.0)a
t½ for KF23 (days) 2.9 (2.1–3.7) 8.8 (7.2–10.6)a 2.7 (2.2–3.3)a 8.9 (7.5–10.0)a
t½ for KB21 and KB32 (days) 22 (14.8–33.2) 20 (14.7–27)
EFF: haloperidol 2.4 (1.43–2.84) —
EFF: paliperidone 0.0198 (0.011–0.032) —
EFF: ziprasidone 0.0089 (0.0045–0.0142) —
EFF: JNJ-37822681 0.0194 (0.0112–0.029) —
EFF: olanzapine 0b 0b
Effect of residence in Eastern 
Europe on KB21 and KB32




RO50 (%) — 86.5d (75.9–95.3)
γ (shape parameter) — 1.3d (0.78–4.8)e
OFV 7,740 (7,130–8,281) 7,963 (7,426–8,451)
aShared parameter estimates. bOlanzapine not included in final estimation, estimating olanzapine with all data caused model to crash, olanzapine alone yielded 
negative effect, and fixing EFF to zero had no significant effect on other parameters. cThe covariate effect was expressed as a proportional increase in the parameter 
value by the covariate. dSingle drug effect parameter was estimated. eγ does not appear to be significantly different from 1 as 1 is included in confidence interval: 1.3 
(0.78–4.8).





Predicted overall EPS incidence coincides with observed 
incidence (table 2). The number of transitions simulated 
from the model was found to be reasonably consistent with 
the observed number of transitions as shown for the paliperi-
done data (Figure 5).
DiScuSSion
This work describes a pharmacokinetic–pharmacodynamic 
modeling approach that successfully characterized the tempo-
ral course of the proportions of patients experiencing different 
grades of EPS following exposure to one of four different APs 
or placebo. The dependency of a future EPS event on the cur-
rent state was accounted for by using a compartmental struc-
ture, defined by differential equations, for the probabilities of 
observing each severity grade at any time point (Figure 2).9,11 
The probabilities were thereby continuous with respect to time 
and coupled to the observed scores through a probabilistic 
model. Markov elements can also be incorporated in a pro-
portional odds model,12 however, that type of model is discrete 
in time and the sampling times and frequencies can greatly 
influence the parameter estimates.13 The analyzed studies 
included self-reported EPS events, and consequently the 
EPS observations were not equally spaced in time. Therefore, 
the continuous time Markov modeling approach was chosen 
and was shown to effectively handle the dependency between 
successive observations of ordered adverse events.
The simultaneous fit of the model to all data resulted in one 
set of parameter estimates that to an adequate degree could 
simulate the proportions of patients experiencing EPS after 
treatment with one of four different compounds studied in 
seven different trials (Figure 4). The simulations of the transi-
tions between different states show that the model cannot re-
create exactly every transition seen in the data, but in relation 
to the huge differences between the occurrence of the differ-
ent transition types, from 0.1% to above 90%, we conclude 
that the overall pattern of transitions can be described by 
the model (Figure 5). A linear model with respect to steady-
state concentrations was better than using the predicted 
D2-receptor occupancy as a direct link to EPS. The findings 
shown in Figure 3 concur with what de Greef et al.4 found 
on the metadata level, where the incidence rate increases 
at occupancy >80%. The fact that separation between the 
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Figure 3 Probabilities of extrapyramidal symptom (EPS) events for the C
ss
 model vs. predictions of drug occupancy based on C
ss
. Green is the 
probability of never experiencing EPS. Black is the probability of experiencing mild but never moderate/severe EPS. Red is the probability of ever 
experiencing moderate/severe EPS. All probabilities are based on 6-week trials.




not possible, and the substantially higher objective function 
value for the D2RO model, suggests the information content 
in the predicted D2RO was relatively low. This indicates that 
the extrapolation of D2RO from position emission tomography 
studies may not be perfect or that receptor systems other 
than D2 are being involved, which is also what is believed to 
be the case for ATAPs.
The change in parameter estimates between inpatient and 
outpatient periods implies that moderate/severe AEs are more 
likely during hospitalization and that AE events were shorter 
while being inpatients, e.g., because of better access to care-
givers and rescue medication. A 100% increase in forward rate 
constants corresponds to a 50% decrease of the half-time to 
having a certain probability of an event, as compared with pla-
cebo. The model dependent on the D2-receptor occupancy is 
not drug dependent and can be used to predict EPS for a new 
D2-receptor antagonist using the drug Kd and information on 
the typical pharmacokinetic profile. The model can also simu-
late the longitudinal correlations seen in EPS AE data.
The model predicts an asymptotic decline of the rate con-
stants towards zero at infinite time. Extrapolation of the model 
into time frames substantially longer than the trial length of 6 
weeks is therefore not endorsed.
It has been suggested that ATAPs induce EPS4 at a lower 
rate than typical antipsychotics. The EPS occurrence rate 
was ~16 times higher for haloperidol than for ATAPs. Halo-
peridol exhibited higher EPS occurrence rate even at the 
lower doses of ≤10 mg/day.
The open-label study of haloperidol with higher doses and 
higher EPS incidence could potentially influence the esti-
mates for haloperidol. A visual predictive check per study 
did, however, show that the present model could predict EPS 
after haloperidol both in the open-label study and when used 
as comparator (data not shown).
Study region was found to be an important covariate wherein 
patients who had studied in Eastern Europe had a lower inci-
dence and shorter average event lengths of EPS than those 
from other countries. The reason for this is not clear, but regional 
differences in study results are not uncommon; different atti-
tudes toward reporting adverse events could be a possibility.
The present EPS model did not consider dropout. How-
ever, EPS was not the major reason for discontinuation of 
treatment, and discontinuation, primarily, was due to lack of 
efficacy and subject’s choice.
Overall, this data analysis indicated that olanzapine was 
well tolerated in patients with schizophrenia as it was not 
possible to estimate a slope parameter for the effect (EFF in 
Eq. 3) due to model instability when including the olanzapine 
data. It may be that olanzapine has a favorable EPS profile14 
due to binding to receptors such as 5-HT2A, but that olan-
zapine would truly have lower incidence rates than placebo 
seems unlikely. Fixing the olanzapine effect to zero and esti-
mate using all data did not change the other parameters sig-
nificantly, but as modeling the olanzapine data alone yielded 
a negative effect, and due to the model instability, the data 
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Figure 4 Visual predictive checks showing the proportions of the patients at each extrapyramidal symptoms (EPS) state on planned visits in the 
observed data (red lines) with the corresponding 95% prediction intervals as constructed from 100 simulations (light blue region) for different 
antipsychotics, using C
ss





In conclusion, a model that can characterize the temporal 
course of the proportions of patients experiencing different 
grades of EPS using a compartmental model structure incor-
porating Markov elements was successfully developed. To our 
knowledge, this approach has not been used for character-
izing side effect data in general, and no population models 
have been developed for EPS side effects. The approach 
could be used for any adverse event with severity grading 
and a reported duration. The model quantifies the relationship 
between the occurrence of EPS and movement to higher EPS 
states and the different predictors of exposure (dose, C
ss
), as 
well as receptor occupancy of the different APs.
MethoDS
Studies, patients, and EPS scores. The EPS modeling 
used individual-level data obtained from six randomized, 
placebo-controlled, clinical trials and one open-label study 
conducted in schizophrenic patients. The study durations 
ranged from 4 to 12 weeks, following oral administration 
of one of five APs (haloperidol, olanzapine, paliperidone-
extended release, ziprasidone, and JNJ-37822681). The 
studies were included on the basis of availability of EPS 
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Figure 5 Visual predictive check of Markov model transitions for paliperidone treatment. The gray area represents the 10th and 90th interpercentile 
range of the simulated number of transitions. Solid line indicates the median observed transitions.




EPS-related AEs included side effects that were reported 
spontaneously by patients over the study period. The impor-
tant AEs documented were akathisia, hyperkinesia, dystonia, 
Parkinsonism, dyskinesia, tardive dyskinesia, hypokinesia, 
and tremor. As the total number of events was too low for 
some AEs to draw conclusions about the exposure–response 
relationship, not all types of EPS-related AEs were observed 
in all trials and there were unspecified EPS AEs as well; the 
model was developed without discriminating between the dif-
ferent types of AEs.
According to the design of the studies, patients met clini-
cians in the clinic at least once a week during the total study 
duration. Patients were directed to record the incidence of 
EPS, the duration of the EPS episode, and resolution of any 
EPS, the severity of which was graded by clinicians on a scale 
from 0 to 3 (0: no EPS, 1: mild EPS, 2: moderate EPS, and 
3: severe EPS). Thus, transitions were possible on any day 
and not only on visit days. If the patient dropped out before 
the end of the study, all available EPS scores until the day of 
dropout were included in the analysis. If several manifesta-
tions of EPS were experienced simultaneously, but differing 
in grade, the grade was set to the highest. In all trials, patients 
were hospitalized for the first 2–3 weeks of the study period.
Data were analyzed by nonlinear mixed-effects modeling 
using the LAPLACE method in NONMEM 7, level 1.2,15 with 
front-end interface PsN 3.4.2.16 R version 2.11 and higher 
versions were used for data management purposes and gen-
erating graphic outputs.17
Pharmacokinetics. A patient-specific average steady-state 
concentration (C
ss
) was calculated using post hoc Bayes-
ian estimates of clearance (C
ss
 = Dose/(CL/F × T ) where T 
is the dosing interval) obtained from previously developed 
pharmacokinetic models.18,19 The typical apparent clearance 
(CL/F) estimates were 88 l/h for haloperidol, 14 l/h for pali-
peridone, 20 l/h for olanzapine, 54 l/h for ziprasidone, and 25 
l/h for JNJ-37822681. The calculated individual C
ss
 was then 
linked to the time course of EPS incidence. C
ss
 was set at 0 
for subjects receiving placebo and was considered constant 
over time.
EPS and likelihood model structure. EPS events were catego-
rized on an ordered categorical scale based on the intensity 
of EPS-related AEs. Because there were few observations on 
severe EPS, the moderate and severe EPS states were com-
bined and a three-state scale was used. A Markov transition 
model with three compartments (Figure 2) was used where 
each compartment represented the probabilities of a differ-
ent state (no EPS, mild EPS, and moderate/severe EPS). 
The probability at t = 0 was set to 1 for the observed EPS 
state. The amount corresponding to probability was allowed 
to distribute between the compartments, and the first-order 
rate constants between the compartments were estimated. 
After an observation, all compartments were reset to zero 
and the compartment corresponding to the observed EPS 
state of the patient was initialized with a 100% probability, 
t was not reset at each event. The model for the probabili-
ties given the data is shown in Eq. 5 where the probability 
of Yij, the observed state at the jth observation of individual 
i, is given by the amount in the compartment corresponding 
to state k at observation j for individual i. The likelihood was 
evaluated at scheduled time points (typically once per week) 
and at state changes on nonscheduled days
(5)
Effects of time, drug exposure, receptor occupancy, and 
covariates on transition probabilities were evaluated in the 
Markov model as a proportional relation on the transition 
rate parameters. Drug and covariate effects were tested on 
each transition parameter separately and in combination. 
The model control stream can be found as  Supplementary 
table S1 online together with an example data set.
Placebo effect and drug effect. Various functions such as 
constant, linear, exponential, and Weibull functions were 
explored for describing a change over time in the transition 
probability rate constants. The antipsychotic drug exposure 
was related to the EPS incidence with increasing complexity 
using linear, E
max
, and sigmoid E
max
 models and tested on top 
of parameters estimated for the placebo group. To character-
ize the relationship between EPS incidence and dopamine 
D2RO levels, the following relationship was used to calculate 
D2RO for each patient:
where RO
max
 is the maximum receptor occupancy and Kd is 
the plasma level of antipsychotic drug associated with 50% of 
RO
max
. The values of Kd for D2-receptor binding were obtained 
from the literature, where E
max
 models were used to fit D2RO 
and plasma drug concentration data obtained from position 
emission tomography studies. The Kd values for D2-receptor 
binding (assuming RO
max
 100%) were 0.56 ng/ml for haloperi-
dol, 12 ng/ml for olanzapine, 4.9 ng/ml for paliperidone, 33 ng/
ml for ziprasidone,20 and 15 ng/ml for JNJ-37822681.21
Covariate model. Influences of patient- and study-specific 
covariates were evaluated as possible explanatory variables 
for the individual variability in the model parameters (table 1). 
The potential effect of concomitant medications for treating 
EPS was tested using the data from paliperidone trial where 
exact time of start and stop of these medications were known.
Covariates were included in the model using different func-
tional forms: linear, piecewise linear, power, and exponential 
functions.19 Only nonmissing, clinically relevant, and uncor-
related covariates that met the predefined statistical criteria 
(P < 0.05) were included in the EPS model.
Final model selection and model evaluation. During initial 
model building, differences in the objective function value (cut 
off: 3.84) between the models together with % relative stan-
dard error (from NONMEM covariance step) of the parameters 
were used to guide the selection of the model. A bootstrap 
analysis (1,000 samples) was carried out, for both the drug 
exposure-EPS and the receptor occupancy-EPS models, to 
check the precision of the estimates and to construct a 95% 
confidence interval for each of the parameter estimates. The 
adequacy of the model was investigated with simulation-
based visual predictive checks. Briefly, prediction intervals of 











the proportions of patients at each EPS state at each planned 
observation and transitions between the different EPS states 
were constructed using 100 (due to heavy calculations) simu-
lated replicates of the initial data set and compared with the 
corresponding observed proportions or transitions.
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Study highlights
what iS the current KnowleDge on  
the toPic?
Data comprising spontaneously reported, graded, 
adverse events are difficult to analyze and have been 
modeled through proportional odds or logistic models 
that require categorization or binning of the data.
what QueStion DiD thiS StuDY aDDreSS?
The study investigated if the severity and duration of 
adverse events can be simultaneously modeled based 
on individual-level data and if there is a set of system 
parameters for the five different compounds included 
in the analysis that could be used in drug develop-
ment for predicting EPS-related events of D2-receptor 
antagonists.
what thiS StuDY aDDS to our KnowleDge
A compartment-based Markov model can successfully 
describe and simulate longitudinal adverse event data 
in patients with schizophrenia treated with D2-receptor 
antagonists.
how thiS Might change clinical 
PharMacologY anD theraPeuticS
The model can be applied in drug development to charac-
terize and simulate time courses of EPS-related adverse 
events and for the prediction of EPS in patients based on 
phase I occupancy data.
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